HSDL2 and cholangiocarcinoma: The log-rank test of two independent cohort datasets from the GEPIA database indicated that CCA patients with low HSDL2 expression had a shorter disease-free survival time than those with high expression (Fig. 1F), but the difference in overall survival was not statistically significant (Fig. 1G).